ATML News Atmel Corp 8.78 $ATML
Allegiance Bancshares, Inc. to Participate in the Piper Jaffray Bank Symposium
GlobeNewswire - Fri Dec 11, 4:05PM CST
Allegiance Bancshares, Inc. (NASDAQ:ABTX), the holding company of Allegiance Bank (collectively, "Allegiance"
, today announced that its management team will participate in the Piper Jaffray Bank Symposium to be held in Palm Beach, Florida on December 14, 2015. The presentation used in the investor meetings will be available in the Investor Relations section of Allegiance's website at www.allegiancebank.com on December 14, 2015.
ABTX: 23.25 (-0.90)
Newly Listed Allegiance Bancshares, Inc. Rings NASDAQ Closing Bell
GlobeNewswire - Thu Nov 12, 12:50PM CST
Allegiance Bancshares, Inc. (NASDAQ:ABTX), the holding company of Allegiance Bank (collectively, "Allegiance" , celebrated its recent listing by ringing the closing bell at the NASDAQ MarketSite in Times Square, in New York City on Friday, November 6, 2015.
ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. (Nasdaq:ABTX) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Nov 05, 9:00AM CST
What:
ABTX: 23.25 (-0.90), NDAQ: 55.67 (+0.81)
Allegiance Bancshares, Inc. Reports Solid Third Quarter 2015 Earnings
GlobeNewswire - Fri Oct 30, 4:20PM CDT
-- Diluted earnings per common share of $0.40 for the third quarter 2015 compared to $0.36 for the second quarter 2015
ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. Announces Third Quarter 2015 Earnings Call and Conference Call Schedule
GlobeNewswire - Tue Oct 20, 11:54AM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance" , the holding company of Allegiance Bank, today announced that it will hold a conference call to discuss its third quarter results on Monday, November 2, 2015 at 9:00 a.m. Central (10:00 a.m. Eastern). The conference call will be hosted by George Martinez, Chairman and CEO, Steve Retzloff, President, and Larry Lehman, Executive Vice President and CFO. The related earnings release will be issued following the close of the market on Friday, October 30, 2015 and will also be available on the Investor Relations section of the website at www.allegiancebank.com, under Financial Information.
ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Wed Oct 14, 12:30PM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance" , the holding company of Allegiance Bank, a Texas state chartered bank, announced today that it has completed the previously announced initial public offering of 2,990,000 shares of its common stock to the public at $21.00 per share for gross proceeds of approximately $62.8 million (including 390,000 shares subject to the underwriters' over-allotment option, which was exercised in full on October 9, 2015). Allegiance's common stock began trading on the NASDAQ Global Market on October 8, under the ticker symbol "ABTX."
ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Oct 07, 7:44PM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance" , the holding company of Allegiance Bank, a Texas state chartered bank, announced today the pricing of its initial public offering of 2,600,000 shares of common stock at $21.00 per share for gross proceeds of approximately $54.6 million. Shares are expected to begin trading tomorrow, October 8, 2015, on the NASDAQ Global Market under the ticker symbol "ABTX."
ABTX: 23.25 (-0.90)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - 10 mins ago
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 7.68 (+0.57), NRX: 2.23 (+0.79), AKBA: 10.96 (+1.21), BSI: 3.60 (+3.26)
Akebia Secures Asian Partner and Funding for Anemia Pill
at The Street - Mon Dec 14, 6:01AM CST
Mitsubishi will pay Akebia $40 million upfront to license vadadustat for the Asian market. The Japanese drug maker will also contribute another $60 million towards Akebia'a global phase III program.
FGEN: 29.22 (+0.35), AKBA: 10.96 (+1.21)
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
Business Wire - Mon Dec 14, 6:00AM CST
--- Akebia to Host Conference Call at 8:30 AM Eastern Time Today -
AKBA: 10.96 (+1.21)
Akebia Therapeutics reports 3Q loss
Automated Insights - Mon Nov 09, 6:35AM CST
CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Monday reported a loss of $19.5 million in its third quarter.
AKBA: 10.96 (+1.21)
Akebia Announces Third Quarter 2015 Financial Results
GlobeNewswire - Mon Nov 09, 6:00AM CST
-Positive Phase 2 data of vadadustat in Dialysis Dependent Chronic Kidney Disease (CKD) Patients Presented at American Society of Nephrology (ASN) Kidney Week-
AKBA: 10.96 (+1.21)
Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting
GlobeNewswire - Sat Nov 07, 2:00PM CST
- Vadadustat Maintained Stable Hemoglobin Levels in All Three Dose Cohorts Following Conversion from rESA Therapy -
AKBA: 10.96 (+1.21)
Global Colitis Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/tg9gvp/colitis) has announced the addition of the "Colitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akebia Therapeutics, Inc. - Amorepacific Corporation - Bayer AG - Dr. Falk Pharma GmbH - Galapagos NV - GeneFrontier Corporation - Innate Pharma SA - Nivalis Therapeutics, Inc. - Peptinov SAS - Prokarium Limited - Protalix BioTherapeutics, Inc. - RDD Pharma Ltd. - Saniona AB - Synovo GmbH For more information visit http://www.researchandmarkets.com/research/tg9gvp/colitis
NVLS: 7.93 (-0.03), AKBA: 10.96 (+1.21), GLPG: 57.15 (-0.38)
UPDATE: Akebia to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Thu Nov 05, 4:37PM CST
In a release issued previously by Akebia Therapeutics, Inc. (NASDAQ:AKBA), the company is updating the presentation time to 3:00 p.m. Mountain Time instead of 3:30 p.m. Mountain Time. The updated release follows:
AKBA: 10.96 (+1.21)
Akebia to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Tue Nov 03, 4:48PM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Jason A. Amello, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10, 2015 at 3:30 p.m. Mountain Time. The conference will take place at The Phoenician resort, in Scottsdale, Arizona.
AKBA: 10.96 (+1.21)
Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting
GlobeNewswire - Wed Oct 28, 3:53PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the vadadustat (formerly AKB-6548) development program will be presented at the upcoming American Society of Nephrology (ASN) Kidney Week 2015 annual meeting in San Diego, California from November 3-8, 2015.
AKBA: 10.96 (+1.21)
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Akebia Therapeutics, Inc. on Behalf of Investors
Business Wire - Tue Oct 13, 8:09PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Akebia Therapeutics, Inc. ("Akebia" or the "Company" (AKBA). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
AKBA: 10.96 (+1.21)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akebia Therapeutics, Inc. - AKBA
Business Wire - Thu Oct 08, 10:28AM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) resulting from allegations that Akebia Therapeutics may have issued materially misleading business information to the investing public.
AKBA: 10.96 (+1.21)
Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program
Business Wire - Tue Oct 06, 7:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA) and the Scientific Advice Process with the European Medicines Agency (EMA) for its lead product, vadadustat (formerly AKB-6548), for patients with anemia related to non-dialysis dependent chronic kidney disease (NDD-CKD). The company has reached agreement with both the FDA and EMA regarding key elements of the Phase 3 program, known as the PRO2TECT(TM) program, and expects to launch the program later this year.
AKBA: 10.96 (+1.21)
Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead
at The Street - Fri Oct 02, 5:09AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ARWR: 5.59 (-0.05), AZN: 32.81 (-0.44), AMGN: 155.55 (+0.40), FGEN: 29.22 (+0.35), AKBA: 10.96 (+1.21), CUR: 1.03 (+0.01)
Market Update on the Healthcare Sector - Amedica, Accuray, Acadia Healthcare, ANI Pharmaceuticals, and Akebia Therapeutics
PR Newswire - Mon Sep 28, 7:33AM CDT
ACI Association has initiated research coverage on the following equities: Amedica Corporation (NASDAQ: AMDA), Accuray Incorporated (NASDAQ: ARAY), Acadia Healthcare Company, Inc. (NASDAQ: ACHC), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Akebia Therapeutics, Inc. (NASDAQ: AKBA). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
ACHC: 62.90 (-0.26), ANIP: 41.67 (-0.94), AKBA: 10.96 (+1.21), ARAY: 6.36 (-0.01), AMDA: 0.13 (-0.02)
Biotech Poised to Rebound: 5 Growth Picks
Swarup Gupta - Zacks Investment Research - Tue Sep 15, 10:36AM CDT
The NASDAQ Biotechnology Index has already embarked upon a recovery this month, increasing 3.3%, and is poised for further gains.
RGEN: 27.64 (-0.46), ZSPH: 89.84 (unch), CLVS: 31.89 (-0.06), GILD: 99.96 (-0.07), VTAE: 14.20 (-0.59), VVUS: 0.97 (-0.03), AKBA: 10.96 (+1.21), BMY: 67.92 (+0.30), AFFX: 9.19 (+0.05), REGN: 534.98 (+0.47)
Akebia (AKBA) Skyrockets on Encouraging Phase II Data
Zacks Equity Research - Zacks Investment Research - Thu Sep 10, 3:35PM CDT
Akebia Therapeutics, Inc. (AKBA) announced positive top-line data from a phase II study on its lead candidate, vadadustat, in dialysis patients with anemia related to chronic kidney disease.
VRX: 93.74 (+0.68), AKBA: 10.96 (+1.21), INFI: 7.41 (+0.11), AMAG: 26.08 (-0.69)
Akebia to Present at the 2015 Morgan Stanley Global Healthcare Conference
Business Wire - Thu Sep 10, 3:30PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18,2015 at 10:30 a.m. Eastern Time. The conference will take place at the Grand Hyatt in New York City.
AKBA: 10.96 (+1.21), MS: 31.89 (-0.19)
Akebia Therapeutics Announces Additions to its Management Team
Business Wire - Thu Sep 10, 3:05PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced three additions to its senior management team: Teresa Compton, PhD joined Akebia as Senior Vice President and Chief Scientific Officer, Ramin Farzaneh-Far, MD as Vice President of Medical Research, and Ed Joyce as Vice President, Investor Relations and Corporate Communications.
GMED: 26.65 (+0.35), ROG: 51.06 (-0.31), AKBA: 10.96 (+1.21)
Why Akebia Therapeutics' Shares Are Soaring 53% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Sep 09, 1:19PM CDT
Akebia Therapeutics President & CEO John Butler presenting at the American Kidney Fund What: After reporting positive phase 2 trial results for its anemia drug, shares in Akebia Therapeutics jumped by 53% earlier today. So what: ...
AKBA: 10.96 (+1.21)
Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - 1 hr 11 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 187.79 (-4.18), CBIO: 2.14 (-0.13), ALXN: 190.21 (+2.15), GSK: 38.96 (-0.35), NVS: 84.73 (+0.21)
Apple Gets Bullish Call; GoPro Downgraded, Adobe Hiked
at Investor's Business Daily - Fri Dec 11, 3:57PM CST
Apple (AAPL) was started with a bullish analyst rating Friday, while GoPro (GPRO) was downgraded and Adobe Systems (ADBE) got a series of price target hikes. BMO Capital initiated coverage on Apple with an outperform rating. Earlier this week, Piper...
GPRO: 16.69 (-2.46), ALXN: 190.21 (+2.15), STZ: 137.57 (-0.73), HPQ: 12.18 (-0.03), AAPL: 111.23 (-1.95), CVC: 30.02 (-0.12), HPE: 14.25 (+0.07), ADBE: 91.29 (-0.13)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/zkbpps/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Actelion Ltd - Adienne Pharma & Biotech - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Cancer Treatment International Limited - Biogen, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Cell2B S.A. - CytoDyn Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - GlaxoSmithKline Plc - ImmuNext, Inc. - Immunomedics, Inc. - Jazz Pharmaceuticals Plc - Kadmon Corporation, LLC - Kamada Ltd. - Kiadis Pharma B.V. - Kymab Limited - Neopharm Ltd. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmicell Co., Ltd. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Rigel Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Spherium Biomed S.L. - Therapix Biosciences Ltd - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/zk...ersus_host
IMMU: 2.99 (unch), BMY: 67.97 (+0.35), GSK: 38.96 (-0.35), RIGL: 3.24 (+0.08), CLBS: 1.08 (+0.02), BLCM: 18.08 (-0.25), SGEN: 39.94 (-0.63), JAZZ: 133.19 (-1.07), ALXN: 190.21 (+2.15), KMDA: 4.09 (-0.14), ABBV: 54.19 (+0.15), ATHX: 1.01 (-0.01), NVS: 84.73 (+0.21)
How Gilead's Dividend Can Inject Cash and Growth in Your Portfolio
at The Street - Fri Dec 11, 6:06AM CST
Beyond its dividend, Gilead Sciences projects healthy stock gains in the quarters ahead.
BIIB: 280.43 (-3.03), GILD: 100.11 (+0.08), XBI: 65.53 (-0.20), ALXN: 190.21 (+2.15)
Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting
Business Wire - Thu Dec 10, 4:00PM CST
--- Interim Phase 2 Data of ALXN1007 Show 28-Day Overall Acute Response Rate in Patients with GI-GVHD -
ALXN: 190.21 (+2.15)
Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting
Business Wire - Thu Dec 10, 5:37AM CST
--- Interim Phase 2 Data of ALXN1007 in Patients with GI-GVHD to be Presented -
ALXN: 190.21 (+2.15)
Alexion (ALXN) Gains after Kanuma Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 2:35PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA has cleared its enzyme replacement therapy, Kanuma.
ALXN: 190.21 (+2.15), BXLT: 37.97 (+0.93), ANIK: 37.21 (+0.21)
Pharmerging Markets 2016-2020
M2 - Wed Dec 09, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mhxgh/pharmerging) has announced the addition of the "Pharmerging Markets 2016-2020" report to their offering. This new report predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases. The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Global pharmaceuticals market PART 06: Pharmerging markets PART 07: Market landscape PART 08: Market segmentation based on geography PART 09: Market overview of Tier I countries PART 10: Market overview of Tier II countries PART 11: Market overview of Tier III countries PART 12: Market drivers PART 13: Impact of drivers PART 14: Market challenges PART 15: Impact of drivers and challenges PART 16: Market trends PART 17: Vendor landscape 20 of 45 Companies Mentioned: - AstraZeneca - GlaxoSmithKline - Merck - Novartis - Pfizer - Sanofi - Abbott Laboratories - AbbVie - Alexion Pharmaceuticals - Allergan - Amgen - Aspen - Astellas Pharma - Baxter - Bayer - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/9m...harmerging
AGN: 301.58 (-0.49), ABT: 44.45 (+0.09), MRK: 52.02 (-0.13), ALXN: 190.21 (+2.15), AMGN: 155.54 (+0.39), GSK: 38.96 (-0.35), BMY: 67.96 (+0.34), NVS: 84.73 (+0.21), CELGZ: 1.00 (-0.09)
Alexion Pharmaceuticals
at Investor's Business Daily - Tue Dec 08, 5:53PM CST
Alexion Pharmaceuticals (ALXN) won FDA approval for rare-disease drug Kanuma, representing its third-ever drug approval. The FDA approved Kanuma for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious organ damage and...
ALXN: 190.21 (+2.15)
Instant Analysis: Alexion Pharmaceuticals Inc Wins an Important FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Tue Dec 08, 3:22PM CST
What happened? Rare disease focused A lexion Pharmaceuticals shared good news today that Kanuma, its treatment for lysosomal acid lipase deficiency -- or LAL-D -- won FDA approval. LAL-D is an awful, ultra-rare genetic metabolic disease in...
ALXN: 190.21 (+2.15)
Alexion Wins Third Drug Approval; Stock Rises
at Investor's Business Daily - Tue Dec 08, 1:18PM CST
Big-cap biotech Alexion Pharmaceuticals (ALXN) won FDA approval Tuesday for rare-disease drug Kanuma, representing its third-ever drug approval. Kanuma was approved for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious...
ALXN: 190.21 (+2.15)
ADDING MULTIMEDIA FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Business Wire - Tue Dec 08, 11:52AM CST
--- Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET -
ALXN: 190.21 (+2.15)
FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Business Wire - Tue Dec 08, 10:52AM CST
--- Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET -
ALXN: 190.21 (+2.15)
How it All Plays Out - Research on LinkedIn, Micron Technology, Alexion Pharmaceuticals and Fitbit
ACCESSWIRE - Tue Dec 08, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 8, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LinkedIn Corp. (NYSE: LNKD), Micron Technology Inc. (NASDAQ: MU), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) and Fitbit Inc. (NYSE: FIT). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FIT: 28.98 (-0.52), MU: 13.72 (-0.32), LNKD: 230.29 (-0.32), ALXN: 190.21 (+2.15)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.93%
Comtex SmarTrend(R) - Mon Dec 07, 4:35PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $176.63 to a high of $183.25. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $179.84 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 190.21 (+2.15)
Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscore Devastating Nature of PNH and Benefits of Soliris(R) (eculizumab) Treatment
Business Wire - Mon Dec 07, 3:05PM CST
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that researchers presented data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry that advance the understanding of PNH and provide important information for the medical community on the long-term management of the disease, including the progression of symptoms in untreated patients with PNH and the continued benefits of ongoing Soliris(R) (eculizumab) treatment regardless of transfusion history. Researchers also presented data from a long-term follow-up study evaluating the effectiveness of Soliris in preventing thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are severe, ultra-rare diseases caused by chronic uncontrolled complement activation. These data were presented at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando.
ALXN: 190.21 (+2.15)
Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 190.21 (+2.15), IBIO: 0.58 (+0.03), FOLD: 9.32 (-0.09)
Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 2.05% Yesterday
Comtex SmarTrend(R) - Wed Dec 02, 6:30PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $175.83 to a high of $179.84. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $177.57 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 190.21 (+2.15)
Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved
Arpita Dutt - Zacks Investment Research - Wed Dec 02, 1:09PM CST
Repros (RPRX) leads the headlines in a relatively slow Thanksgiving week with the FDA issuing a CRL for the company's experimental secondary hypogonadism treatment.
BIIB: 280.43 (-3.03), GILD: 100.11 (+0.08), ALXN: 190.21 (+2.15), RPRX: 1.24 (+0.02), AMGN: 155.54 (+0.39), ABBV: 54.19 (+0.15), XOMA: 1.27 (unch)
5 Health Care Trades to Buy for December Breakouts
at The Street - Tue Dec 01, 10:15AM CST
To make the most of a bullish turn in momentum in health care stocks, here is a technical look at five stocks to trade for gains.
SHPG: 187.79 (-4.18), ALXN: 190.21 (+2.15), AGIO: 51.46 (-2.28), LLY: 83.74 (+0.45), XRAY: 59.75 (-0.04)
Atmel (ATML) Stock Surges on New Takeover Offer
at The Street - 32 mins ago
Atmel (ATML) stock is rising in early-morning trading on Monday, after the company received a takeover offer of $9 in cash per share.
ATML: 8.78 (+0.32)
Embedded Systems Global Strategic Business Report - Analysis, Trends, Technologies & Forecast 2015-2020
M2 - 2 hrs 57 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n727dv/embedded_systems) has announced the addition of the "Embedded Systems - Global Strategic Business Report" report to their offering. This comprehensive report provides a detailed understanding of the global Embedded Systems market and the various factors predicted to affect this market in the coming years. It considers current and future drivers, challenges and opportunities, resulting in an unrivalled analysis of this market and the confidence needed to make informed business decisions in this market. Data is provided on a global and regional level and the following End-Use Segments: - Computing - Telecommunications - Consumer Electronics - Others The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also included is a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 57 companies including many key and niche players including: - Altera Corporation - ARM Limited - Atmel Corporation - Axiomtek - Freescale Semiconductor, Inc. Report Structure: EMBEDDED SYSTEMS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET TRENDS & DRIVERS 3. PRODUCT OVERVIEW 4. PRODUCT INTRODUCTIONS/INNOVATIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/n7...ed_systems
ATML: 8.78 (+0.32), ALTR: 53.03 (+0.04)
Atmel announces receipt of unsolicited proposal to acquire all outstanding shares of common stock
M2 - Mon Dec 14, 6:28AM CST
Atmel Corporation (Nasdaq:ATML), a provider of microcontroller and touch solutions, announced on Friday that it has received an unsolicited proposal to acquire all of the outstanding shares of Atmel common stock.
ATML: 8.78 (+0.32)
European Stocks Rise as Eurozone Production Jumps
at The Street - Mon Dec 14, 5:23AM CST
European stocks rise on Monday amid a better-than-expected rise in euro-area industrial production and optimism about rate action from the U.S. this week.
ATML: 8.78 (+0.32), RDS.A: 43.57 (-0.97), AZN: 32.85 (-0.40)
Dialog Semiconductor's announces submission of registration statement to US SEC and acknowledges Atmel's receipt of its unsolicited acquisition proposal
M2 - Mon Dec 14, 5:08AM CST
Dialog Semiconductor plc (Xetra
LG) announced on Friday, that consistent with its status as a foreign private issuer, it has confidentially submitted a draft registration statement on Form F-4 with the US Securities and Exchange Commission in connection with its proposed acquisition of Atmel Corporation (Nasdaq: ATML).
ATML: 8.78 (+0.32)
Dialog Semiconductor Plc.: Dialog Semiconductor Announces Submission of Registration Statement and Acknowledges Atmel's Receipt of Unsolicited Proposal
Business Wire - Fri Dec 11, 9:15PM CST
Dialog Semiconductor plc ("Dialog" or "Company" (XETRA: DLG) today announced that, consistent with its status as a foreign private issuer, it has confidentially submitted a draft registration statement on Form F-4 with the United States Securities and Exchange Commission (the "SEC" in connection with its previously announced proposed acquisition of Atmel Corporation (Nasdaq: ATML). The registration statement contains a draft prospectus and proxy statement in connection with the proposed acquisition. The definitive versions of the prospectus and proxy statement will be filed publicly with the SEC and mailed to stockholders of Atmel prior to the time the Atmel shareholder meeting is scheduled.
ATML: 8.78 (+0.32)
Atmel Acknowledges Receipt of Unsolicited Proposal
PR Newswire - Fri Dec 11, 5:00PM CST
Atmel® Corporation (Nasdaq: ATML), a leader in microcontroller and touch solutions, today announced that it has received an unsolicited proposal to acquire all of the outstanding shares of Atmel common stock. Under the terms of the proposal, Atmel stockholders would receive $9.00 in cash per share, with the option to receive, in lieu of cash, shares of the acquiror in an amount of up to $1.0 billion in aggregate value, based on a ten-day trailing average of the acquiror's closing stock price measured as of transaction close.
ATML: 8.78 (+0.32)
Atmel (ATML) Shows Promise with Healthy Organic Growth
Zacks Equity Research - Zacks Investment Research - Mon Dec 07, 10:50AM CST
On Dec 7, Zacks Investment Research updated the research report on leading microcontroller and touch solutions provider Atmel Corporation (ATML).
ATML: 8.78 (+0.32), ANAD: 0.37 (unch), FORM: 8.42 (-0.09), AMCC: 6.46 (-0.12)
BUYINS.NET: ATML SqueezeTrigger Price is $8.24. There is $109,030,032 That Short Sellers Still Need To Cover.
M2 - Wed Dec 02, 10:30PM CST
November 18, 2015
ATML: 8.78 (+0.32)
Avnet Celebrates Silver Anniversary in the Americas with Atmel
M2 - Wed Dec 02, 9:20PM CST
November 19, 2015
ATML: 8.78 (+0.32), AVT: 43.78 (-0.54)
Atmel Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Fri Nov 27, 5:38PM CST
Atmel (NASDAQ:ATML) traded in a range yesterday that spanned from a low of $8.52 to a high of $8.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $8.53 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ATML: 8.78 (+0.32)
Atmel Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 24, 5:09PM CST
Atmel (NASDAQ:ATML) traded in a range yesterday that spanned from a low of $8.30 to a high of $8.44. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $8.39 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ATML: 8.78 (+0.32)
Atmel (ATML) Stock Rallies, Dialog Stockholders Support $4.6 Billion Deal
at The Street - Thu Nov 19, 10:55AM CST
Atmel (ATML) shares are higher on Thursday after Dialog Semiconductor shareholders approved the company's $4.6 billion takeover of Atmel.
ATML: 8.78 (+0.32)
Exosite Launches New Partner Program - Exosite IoT Alliance
Business Wire - Thu Nov 19, 9:00AM CST
Exosite (www.exosite.com), whose enterprise-grade cloud platform accelerates the time-to-market for IoT solutions, announced the Exosite IoT Alliance, a collaboration of edge devices, communication, business systems and software, and solution providers. The Exosite IoT Alliance is an ecosystem of like-minded companies and technology providers focused on advancing innovation in the digital enterprise and accelerating the overall adoption of IoT.
ATML: 8.78 (+0.32), MCHP: 44.41 (-0.23)
Dialog Semiconductor Announces Resolution in respect of the ATMEL Acquisition has been Passed at the General Meeting
Business Wire - Thu Nov 19, 7:45AM CST
Dialog Semiconductor plc (XETRA LG) today announced that at an extraordinary general meeting of shareholders held today, the Dialog shareholders have approved the allocation of shares required to complete the company's previously announced acquisition of Atmel Corporation (NASDAQ: ATML). The resolution was approved by a vote of 61.94% of the shares represented at the meeting.
ATML: 8.78 (+0.32)
Shareholder Resolution in Favor of the Acquisition of Atmel Has Been Passed at the General Meeting of Dialog Semiconductor
Business Wire - Thu Nov 19, 7:45AM CST
On 20 September 2015, Dialog Semiconductor Plc (XTRA: DLG) ("Dialog" announced that it had entered into a merger agreement pursuant to which it will acquire Atmel Corporation (NASDAQ: ATML). The acquisition is subject to a resolution by Dialog's shareholders granting authority to the board of directors of Dialog to issue and allot new shares in Dialog (the "Resolution" . At today's General Meeting of Dialog, the Resolution has been passed. The total number of shares in issue as at 12.00 noon GMT (1.00 p.m. CET) on 17 November 2015 was 77,865,955 shares. The total number of votes cast was 42,312,471 or 54.34% of the issued share capital. The result of the poll was 26,209,631 or 61.94% votes "For", 16,102,840 or 38.06% votes "Against".
ATML: 8.78 (+0.32)
Allegiance Bancshares, Inc. to Participate in the Piper Jaffray Bank Symposium
GlobeNewswire - Fri Dec 11, 4:05PM CST
Allegiance Bancshares, Inc. (NASDAQ:ABTX), the holding company of Allegiance Bank (collectively, "Allegiance"
, today announced that its management team will participate in the Piper Jaffray Bank Symposium to be held in Palm Beach, Florida on December 14, 2015. The presentation used in the investor meetings will be available in the Investor Relations section of Allegiance's website at www.allegiancebank.com on December 14, 2015. ABTX: 23.25 (-0.90)
Newly Listed Allegiance Bancshares, Inc. Rings NASDAQ Closing Bell
GlobeNewswire - Thu Nov 12, 12:50PM CST
Allegiance Bancshares, Inc. (NASDAQ:ABTX), the holding company of Allegiance Bank (collectively, "Allegiance"
, celebrated its recent listing by ringing the closing bell at the NASDAQ MarketSite in Times Square, in New York City on Friday, November 6, 2015. ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. (Nasdaq:ABTX) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Nov 05, 9:00AM CST
What:
ABTX: 23.25 (-0.90), NDAQ: 55.67 (+0.81)
Allegiance Bancshares, Inc. Reports Solid Third Quarter 2015 Earnings
GlobeNewswire - Fri Oct 30, 4:20PM CDT
-- Diluted earnings per common share of $0.40 for the third quarter 2015 compared to $0.36 for the second quarter 2015
ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. Announces Third Quarter 2015 Earnings Call and Conference Call Schedule
GlobeNewswire - Tue Oct 20, 11:54AM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance"
, the holding company of Allegiance Bank, today announced that it will hold a conference call to discuss its third quarter results on Monday, November 2, 2015 at 9:00 a.m. Central (10:00 a.m. Eastern). The conference call will be hosted by George Martinez, Chairman and CEO, Steve Retzloff, President, and Larry Lehman, Executive Vice President and CFO. The related earnings release will be issued following the close of the market on Friday, October 30, 2015 and will also be available on the Investor Relations section of the website at www.allegiancebank.com, under Financial Information. ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. Announces Closing of Initial Public Offering
GlobeNewswire - Wed Oct 14, 12:30PM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance"
, the holding company of Allegiance Bank, a Texas state chartered bank, announced today that it has completed the previously announced initial public offering of 2,990,000 shares of its common stock to the public at $21.00 per share for gross proceeds of approximately $62.8 million (including 390,000 shares subject to the underwriters' over-allotment option, which was exercised in full on October 9, 2015). Allegiance's common stock began trading on the NASDAQ Global Market on October 8, under the ticker symbol "ABTX." ABTX: 23.25 (-0.90)
Allegiance Bancshares, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Oct 07, 7:44PM CDT
Allegiance Bancshares, Inc. (NASDAQ:ABTX) ("Allegiance"
, the holding company of Allegiance Bank, a Texas state chartered bank, announced today the pricing of its initial public offering of 2,600,000 shares of common stock at $21.00 per share for gross proceeds of approximately $54.6 million. Shares are expected to begin trading tomorrow, October 8, 2015, on the NASDAQ Global Market under the ticker symbol "ABTX." ABTX: 23.25 (-0.90)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - 10 mins ago
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
AVXL: 7.68 (+0.57), NRX: 2.23 (+0.79), AKBA: 10.96 (+1.21), BSI: 3.60 (+3.26)
Akebia Secures Asian Partner and Funding for Anemia Pill
at The Street - Mon Dec 14, 6:01AM CST
Mitsubishi will pay Akebia $40 million upfront to license vadadustat for the Asian market. The Japanese drug maker will also contribute another $60 million towards Akebia'a global phase III program.
FGEN: 29.22 (+0.35), AKBA: 10.96 (+1.21)
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
Business Wire - Mon Dec 14, 6:00AM CST
--- Akebia to Host Conference Call at 8:30 AM Eastern Time Today -
AKBA: 10.96 (+1.21)
Akebia Therapeutics reports 3Q loss
Automated Insights - Mon Nov 09, 6:35AM CST
CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Monday reported a loss of $19.5 million in its third quarter.
AKBA: 10.96 (+1.21)
Akebia Announces Third Quarter 2015 Financial Results
GlobeNewswire - Mon Nov 09, 6:00AM CST
-Positive Phase 2 data of vadadustat in Dialysis Dependent Chronic Kidney Disease (CKD) Patients Presented at American Society of Nephrology (ASN) Kidney Week-
AKBA: 10.96 (+1.21)
Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting
GlobeNewswire - Sat Nov 07, 2:00PM CST
- Vadadustat Maintained Stable Hemoglobin Levels in All Three Dose Cohorts Following Conversion from rESA Therapy -
AKBA: 10.96 (+1.21)
Global Colitis Pipeline Review, H2 2015
M2 - Fri Nov 06, 8:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/tg9gvp/colitis) has announced the addition of the "Colitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akebia Therapeutics, Inc. - Amorepacific Corporation - Bayer AG - Dr. Falk Pharma GmbH - Galapagos NV - GeneFrontier Corporation - Innate Pharma SA - Nivalis Therapeutics, Inc. - Peptinov SAS - Prokarium Limited - Protalix BioTherapeutics, Inc. - RDD Pharma Ltd. - Saniona AB - Synovo GmbH For more information visit http://www.researchandmarkets.com/research/tg9gvp/colitis
NVLS: 7.93 (-0.03), AKBA: 10.96 (+1.21), GLPG: 57.15 (-0.38)
UPDATE: Akebia to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Thu Nov 05, 4:37PM CST
In a release issued previously by Akebia Therapeutics, Inc. (NASDAQ:AKBA), the company is updating the presentation time to 3:00 p.m. Mountain Time instead of 3:30 p.m. Mountain Time. The updated release follows:
AKBA: 10.96 (+1.21)
Akebia to Present at the Credit Suisse 24th Annual Healthcare Conference
GlobeNewswire - Tue Nov 03, 4:48PM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Jason A. Amello, Senior Vice President, Chief Financial Officer and Treasurer, will present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10, 2015 at 3:30 p.m. Mountain Time. The conference will take place at The Phoenician resort, in Scottsdale, Arizona.
AKBA: 10.96 (+1.21)
Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting
GlobeNewswire - Wed Oct 28, 3:53PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the vadadustat (formerly AKB-6548) development program will be presented at the upcoming American Society of Nephrology (ASN) Kidney Week 2015 annual meeting in San Diego, California from November 3-8, 2015.
AKBA: 10.96 (+1.21)
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Akebia Therapeutics, Inc. on Behalf of Investors
Business Wire - Tue Oct 13, 8:09PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Akebia Therapeutics, Inc. ("Akebia" or the "Company"
(AKBA). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. AKBA: 10.96 (+1.21)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akebia Therapeutics, Inc. - AKBA
Business Wire - Thu Oct 08, 10:28AM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akebia Therapeutics, Inc. (NASDAQ: AKBA) resulting from allegations that Akebia Therapeutics may have issued materially misleading business information to the investing public.
AKBA: 10.96 (+1.21)
Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program
Business Wire - Tue Oct 06, 7:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA) and the Scientific Advice Process with the European Medicines Agency (EMA) for its lead product, vadadustat (formerly AKB-6548), for patients with anemia related to non-dialysis dependent chronic kidney disease (NDD-CKD). The company has reached agreement with both the FDA and EMA regarding key elements of the Phase 3 program, known as the PRO2TECT(TM) program, and expects to launch the program later this year.
AKBA: 10.96 (+1.21)
Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead
at The Street - Fri Oct 02, 5:09AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
ARWR: 5.59 (-0.05), AZN: 32.81 (-0.44), AMGN: 155.55 (+0.40), FGEN: 29.22 (+0.35), AKBA: 10.96 (+1.21), CUR: 1.03 (+0.01)
Market Update on the Healthcare Sector - Amedica, Accuray, Acadia Healthcare, ANI Pharmaceuticals, and Akebia Therapeutics
PR Newswire - Mon Sep 28, 7:33AM CDT
ACI Association has initiated research coverage on the following equities: Amedica Corporation (NASDAQ: AMDA), Accuray Incorporated (NASDAQ: ARAY), Acadia Healthcare Company, Inc. (NASDAQ: ACHC), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Akebia Therapeutics, Inc. (NASDAQ: AKBA). On Friday, September 25, 2015, Nasdaq ended at 4,686.50 down 1.01%, Dow Jones advanced 0.70%, to finish the day at 16,314.67, and the S&P closed at 1,931.34, down 0.05%. Register for your complimentary reports at the links given below.
ACHC: 62.90 (-0.26), ANIP: 41.67 (-0.94), AKBA: 10.96 (+1.21), ARAY: 6.36 (-0.01), AMDA: 0.13 (-0.02)
Biotech Poised to Rebound: 5 Growth Picks
Swarup Gupta - Zacks Investment Research - Tue Sep 15, 10:36AM CDT
The NASDAQ Biotechnology Index has already embarked upon a recovery this month, increasing 3.3%, and is poised for further gains.
RGEN: 27.64 (-0.46), ZSPH: 89.84 (unch), CLVS: 31.89 (-0.06), GILD: 99.96 (-0.07), VTAE: 14.20 (-0.59), VVUS: 0.97 (-0.03), AKBA: 10.96 (+1.21), BMY: 67.92 (+0.30), AFFX: 9.19 (+0.05), REGN: 534.98 (+0.47)
Akebia (AKBA) Skyrockets on Encouraging Phase II Data
Zacks Equity Research - Zacks Investment Research - Thu Sep 10, 3:35PM CDT
Akebia Therapeutics, Inc. (AKBA) announced positive top-line data from a phase II study on its lead candidate, vadadustat, in dialysis patients with anemia related to chronic kidney disease.
VRX: 93.74 (+0.68), AKBA: 10.96 (+1.21), INFI: 7.41 (+0.11), AMAG: 26.08 (-0.69)
Akebia to Present at the 2015 Morgan Stanley Global Healthcare Conference
Business Wire - Thu Sep 10, 3:30PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18,2015 at 10:30 a.m. Eastern Time. The conference will take place at the Grand Hyatt in New York City.
AKBA: 10.96 (+1.21), MS: 31.89 (-0.19)
Akebia Therapeutics Announces Additions to its Management Team
Business Wire - Thu Sep 10, 3:05PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced three additions to its senior management team: Teresa Compton, PhD joined Akebia as Senior Vice President and Chief Scientific Officer, Ramin Farzaneh-Far, MD as Vice President of Medical Research, and Ed Joyce as Vice President, Investor Relations and Corporate Communications.
GMED: 26.65 (+0.35), ROG: 51.06 (-0.31), AKBA: 10.96 (+1.21)
Why Akebia Therapeutics' Shares Are Soaring 53% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Sep 09, 1:19PM CDT
Akebia Therapeutics President & CEO John Butler presenting at the American Kidney Fund What: After reporting positive phase 2 trial results for its anemia drug, shares in Akebia Therapeutics jumped by 53% earlier today. So what: ...
AKBA: 10.96 (+1.21)
Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - 1 hr 11 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 187.79 (-4.18), CBIO: 2.14 (-0.13), ALXN: 190.21 (+2.15), GSK: 38.96 (-0.35), NVS: 84.73 (+0.21)
Apple Gets Bullish Call; GoPro Downgraded, Adobe Hiked
at Investor's Business Daily - Fri Dec 11, 3:57PM CST
Apple (AAPL) was started with a bullish analyst rating Friday, while GoPro (GPRO) was downgraded and Adobe Systems (ADBE) got a series of price target hikes. BMO Capital initiated coverage on Apple with an outperform rating. Earlier this week, Piper...
GPRO: 16.69 (-2.46), ALXN: 190.21 (+2.15), STZ: 137.57 (-0.73), HPQ: 12.18 (-0.03), AAPL: 111.23 (-1.95), CVC: 30.02 (-0.12), HPE: 14.25 (+0.07), ADBE: 91.29 (-0.13)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015
M2 - Fri Dec 11, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/zkbpps/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Actelion Ltd - Adienne Pharma & Biotech - Alexion Pharmaceuticals, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Cancer Treatment International Limited - Biogen, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Cell2B S.A. - CytoDyn Inc. - F. Hoffmann-La Roche Ltd. - Generon (Shanghai) Corporation Ltd. - GlaxoSmithKline Plc - ImmuNext, Inc. - Immunomedics, Inc. - Jazz Pharmaceuticals Plc - Kadmon Corporation, LLC - Kamada Ltd. - Kiadis Pharma B.V. - Kymab Limited - Neopharm Ltd. - Novartis AG - Omni Bio Pharmaceutical Inc. - Pharmicell Co., Ltd. - R-Tech Ueno, Ltd. - REGiMMUNE Corporation - Rigel Pharmaceuticals, Inc. - Seattle Genetics, Inc. - Spherium Biomed S.L. - Therapix Biosciences Ltd - Xenikos B.V. For more information visit http://www.researchandmarkets.com/research/zk...ersus_host
IMMU: 2.99 (unch), BMY: 67.97 (+0.35), GSK: 38.96 (-0.35), RIGL: 3.24 (+0.08), CLBS: 1.08 (+0.02), BLCM: 18.08 (-0.25), SGEN: 39.94 (-0.63), JAZZ: 133.19 (-1.07), ALXN: 190.21 (+2.15), KMDA: 4.09 (-0.14), ABBV: 54.19 (+0.15), ATHX: 1.01 (-0.01), NVS: 84.73 (+0.21)
How Gilead's Dividend Can Inject Cash and Growth in Your Portfolio
at The Street - Fri Dec 11, 6:06AM CST
Beyond its dividend, Gilead Sciences projects healthy stock gains in the quarters ahead.
BIIB: 280.43 (-3.03), GILD: 100.11 (+0.08), XBI: 65.53 (-0.20), ALXN: 190.21 (+2.15)
Alexion Highlights Innovative Rare Disease Portfolio at Investor Day Meeting
Business Wire - Thu Dec 10, 4:00PM CST
--- Interim Phase 2 Data of ALXN1007 Show 28-Day Overall Acute Response Rate in Patients with GI-GVHD -
ALXN: 190.21 (+2.15)
Alexion to Highlight Innovative Rare Disease Portfolio at Investor Day Meeting
Business Wire - Thu Dec 10, 5:37AM CST
--- Interim Phase 2 Data of ALXN1007 in Patients with GI-GVHD to be Presented -
ALXN: 190.21 (+2.15)
Alexion (ALXN) Gains after Kanuma Receives FDA Approval
Zacks Equity Research - Zacks Investment Research - Wed Dec 09, 2:35PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA has cleared its enzyme replacement therapy, Kanuma.
ALXN: 190.21 (+2.15), BXLT: 37.97 (+0.93), ANIK: 37.21 (+0.21)
Pharmerging Markets 2016-2020
M2 - Wed Dec 09, 5:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mhxgh/pharmerging) has announced the addition of the "Pharmerging Markets 2016-2020" report to their offering. This new report predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases. The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Global pharmaceuticals market PART 06: Pharmerging markets PART 07: Market landscape PART 08: Market segmentation based on geography PART 09: Market overview of Tier I countries PART 10: Market overview of Tier II countries PART 11: Market overview of Tier III countries PART 12: Market drivers PART 13: Impact of drivers PART 14: Market challenges PART 15: Impact of drivers and challenges PART 16: Market trends PART 17: Vendor landscape 20 of 45 Companies Mentioned: - AstraZeneca - GlaxoSmithKline - Merck - Novartis - Pfizer - Sanofi - Abbott Laboratories - AbbVie - Alexion Pharmaceuticals - Allergan - Amgen - Aspen - Astellas Pharma - Baxter - Bayer - Biogen - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - Chugai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/9m...harmerging
AGN: 301.58 (-0.49), ABT: 44.45 (+0.09), MRK: 52.02 (-0.13), ALXN: 190.21 (+2.15), AMGN: 155.54 (+0.39), GSK: 38.96 (-0.35), BMY: 67.96 (+0.34), NVS: 84.73 (+0.21), CELGZ: 1.00 (-0.09)
Alexion Pharmaceuticals
at Investor's Business Daily - Tue Dec 08, 5:53PM CST
Alexion Pharmaceuticals (ALXN) won FDA approval for rare-disease drug Kanuma, representing its third-ever drug approval. The FDA approved Kanuma for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious organ damage and...
ALXN: 190.21 (+2.15)
Instant Analysis: Alexion Pharmaceuticals Inc Wins an Important FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Tue Dec 08, 3:22PM CST
What happened? Rare disease focused A lexion Pharmaceuticals shared good news today that Kanuma, its treatment for lysosomal acid lipase deficiency -- or LAL-D -- won FDA approval. LAL-D is an awful, ultra-rare genetic metabolic disease in...
ALXN: 190.21 (+2.15)
Alexion Wins Third Drug Approval; Stock Rises
at Investor's Business Daily - Tue Dec 08, 1:18PM CST
Big-cap biotech Alexion Pharmaceuticals (ALXN) won FDA approval Tuesday for rare-disease drug Kanuma, representing its third-ever drug approval. Kanuma was approved for lysosomal acid lipase deficiency (LAL-D), a genetic condition that brings serious...
ALXN: 190.21 (+2.15)
ADDING MULTIMEDIA FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Business Wire - Tue Dec 08, 11:52AM CST
--- Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET -
ALXN: 190.21 (+2.15)
FDA Approves Kanuma(TM) (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D)
Business Wire - Tue Dec 08, 10:52AM CST
--- Conference Call Scheduled for Tuesday, December 8 at 5:00 p.m. ET -
ALXN: 190.21 (+2.15)
How it All Plays Out - Research on LinkedIn, Micron Technology, Alexion Pharmaceuticals and Fitbit
ACCESSWIRE - Tue Dec 08, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 8, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LinkedIn Corp. (NYSE: LNKD), Micron Technology Inc. (NASDAQ: MU), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) and Fitbit Inc. (NYSE: FIT). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
FIT: 28.98 (-0.52), MU: 13.72 (-0.32), LNKD: 230.29 (-0.32), ALXN: 190.21 (+2.15)
Alexion Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.93%
Comtex SmarTrend(R) - Mon Dec 07, 4:35PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $176.63 to a high of $183.25. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $179.84 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALXN: 190.21 (+2.15)
Data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Presented at ASH Annual Meeting Underscore Devastating Nature of PNH and Benefits of Soliris(R) (eculizumab) Treatment
Business Wire - Mon Dec 07, 3:05PM CST
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that researchers presented data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry that advance the understanding of PNH and provide important information for the medical community on the long-term management of the disease, including the progression of symptoms in untreated patients with PNH and the continued benefits of ongoing Soliris(R) (eculizumab) treatment regardless of transfusion history. Researchers also presented data from a long-term follow-up study evaluating the effectiveness of Soliris in preventing thrombotic microangiopathy (TMA) in patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are severe, ultra-rare diseases caused by chronic uncontrolled complement activation. These data were presented at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando.
ALXN: 190.21 (+2.15)
Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 190.21 (+2.15), IBIO: 0.58 (+0.03), FOLD: 9.32 (-0.09)
Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 2.05% Yesterday
Comtex SmarTrend(R) - Wed Dec 02, 6:30PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $175.83 to a high of $179.84. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $177.57 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 190.21 (+2.15)
Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved
Arpita Dutt - Zacks Investment Research - Wed Dec 02, 1:09PM CST
Repros (RPRX) leads the headlines in a relatively slow Thanksgiving week with the FDA issuing a CRL for the company's experimental secondary hypogonadism treatment.
BIIB: 280.43 (-3.03), GILD: 100.11 (+0.08), ALXN: 190.21 (+2.15), RPRX: 1.24 (+0.02), AMGN: 155.54 (+0.39), ABBV: 54.19 (+0.15), XOMA: 1.27 (unch)
5 Health Care Trades to Buy for December Breakouts
at The Street - Tue Dec 01, 10:15AM CST
To make the most of a bullish turn in momentum in health care stocks, here is a technical look at five stocks to trade for gains.
SHPG: 187.79 (-4.18), ALXN: 190.21 (+2.15), AGIO: 51.46 (-2.28), LLY: 83.74 (+0.45), XRAY: 59.75 (-0.04)
Atmel (ATML) Stock Surges on New Takeover Offer
at The Street - 32 mins ago
Atmel (ATML) stock is rising in early-morning trading on Monday, after the company received a takeover offer of $9 in cash per share.
ATML: 8.78 (+0.32)
Embedded Systems Global Strategic Business Report - Analysis, Trends, Technologies & Forecast 2015-2020
M2 - 2 hrs 57 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n727dv/embedded_systems) has announced the addition of the "Embedded Systems - Global Strategic Business Report" report to their offering. This comprehensive report provides a detailed understanding of the global Embedded Systems market and the various factors predicted to affect this market in the coming years. It considers current and future drivers, challenges and opportunities, resulting in an unrivalled analysis of this market and the confidence needed to make informed business decisions in this market. Data is provided on a global and regional level and the following End-Use Segments: - Computing - Telecommunications - Consumer Electronics - Others The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also included is a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 57 companies including many key and niche players including: - Altera Corporation - ARM Limited - Atmel Corporation - Axiomtek - Freescale Semiconductor, Inc. Report Structure: EMBEDDED SYSTEMS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET TRENDS & DRIVERS 3. PRODUCT OVERVIEW 4. PRODUCT INTRODUCTIONS/INNOVATIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/n7...ed_systems
ATML: 8.78 (+0.32), ALTR: 53.03 (+0.04)
Atmel announces receipt of unsolicited proposal to acquire all outstanding shares of common stock
M2 - Mon Dec 14, 6:28AM CST
Atmel Corporation (Nasdaq:ATML), a provider of microcontroller and touch solutions, announced on Friday that it has received an unsolicited proposal to acquire all of the outstanding shares of Atmel common stock.
ATML: 8.78 (+0.32)
European Stocks Rise as Eurozone Production Jumps
at The Street - Mon Dec 14, 5:23AM CST
European stocks rise on Monday amid a better-than-expected rise in euro-area industrial production and optimism about rate action from the U.S. this week.
ATML: 8.78 (+0.32), RDS.A: 43.57 (-0.97), AZN: 32.85 (-0.40)
Dialog Semiconductor's announces submission of registration statement to US SEC and acknowledges Atmel's receipt of its unsolicited acquisition proposal
M2 - Mon Dec 14, 5:08AM CST
Dialog Semiconductor plc (Xetra
LG) announced on Friday, that consistent with its status as a foreign private issuer, it has confidentially submitted a draft registration statement on Form F-4 with the US Securities and Exchange Commission in connection with its proposed acquisition of Atmel Corporation (Nasdaq: ATML). ATML: 8.78 (+0.32)
Dialog Semiconductor Plc.: Dialog Semiconductor Announces Submission of Registration Statement and Acknowledges Atmel's Receipt of Unsolicited Proposal
Business Wire - Fri Dec 11, 9:15PM CST
Dialog Semiconductor plc ("Dialog" or "Company"
(XETRA: DLG) today announced that, consistent with its status as a foreign private issuer, it has confidentially submitted a draft registration statement on Form F-4 with the United States Securities and Exchange Commission (the "SEC" in connection with its previously announced proposed acquisition of Atmel Corporation (Nasdaq: ATML). The registration statement contains a draft prospectus and proxy statement in connection with the proposed acquisition. The definitive versions of the prospectus and proxy statement will be filed publicly with the SEC and mailed to stockholders of Atmel prior to the time the Atmel shareholder meeting is scheduled. ATML: 8.78 (+0.32)
Atmel Acknowledges Receipt of Unsolicited Proposal
PR Newswire - Fri Dec 11, 5:00PM CST
Atmel® Corporation (Nasdaq: ATML), a leader in microcontroller and touch solutions, today announced that it has received an unsolicited proposal to acquire all of the outstanding shares of Atmel common stock. Under the terms of the proposal, Atmel stockholders would receive $9.00 in cash per share, with the option to receive, in lieu of cash, shares of the acquiror in an amount of up to $1.0 billion in aggregate value, based on a ten-day trailing average of the acquiror's closing stock price measured as of transaction close.
ATML: 8.78 (+0.32)
Atmel (ATML) Shows Promise with Healthy Organic Growth
Zacks Equity Research - Zacks Investment Research - Mon Dec 07, 10:50AM CST
On Dec 7, Zacks Investment Research updated the research report on leading microcontroller and touch solutions provider Atmel Corporation (ATML).
ATML: 8.78 (+0.32), ANAD: 0.37 (unch), FORM: 8.42 (-0.09), AMCC: 6.46 (-0.12)
BUYINS.NET: ATML SqueezeTrigger Price is $8.24. There is $109,030,032 That Short Sellers Still Need To Cover.
M2 - Wed Dec 02, 10:30PM CST
November 18, 2015
ATML: 8.78 (+0.32)
Avnet Celebrates Silver Anniversary in the Americas with Atmel
M2 - Wed Dec 02, 9:20PM CST
November 19, 2015
ATML: 8.78 (+0.32), AVT: 43.78 (-0.54)
Atmel Set to Possibly Pullback After Yesterday's Rally of 1.53%
Comtex SmarTrend(R) - Fri Nov 27, 5:38PM CST
Atmel (NASDAQ:ATML) traded in a range yesterday that spanned from a low of $8.52 to a high of $8.60. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $8.53 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ATML: 8.78 (+0.32)
Atmel Falls 1.42% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 24, 5:09PM CST
Atmel (NASDAQ:ATML) traded in a range yesterday that spanned from a low of $8.30 to a high of $8.44. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $8.39 on volume of 12.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ATML: 8.78 (+0.32)
Atmel (ATML) Stock Rallies, Dialog Stockholders Support $4.6 Billion Deal
at The Street - Thu Nov 19, 10:55AM CST
Atmel (ATML) shares are higher on Thursday after Dialog Semiconductor shareholders approved the company's $4.6 billion takeover of Atmel.
ATML: 8.78 (+0.32)
Exosite Launches New Partner Program - Exosite IoT Alliance
Business Wire - Thu Nov 19, 9:00AM CST
Exosite (www.exosite.com), whose enterprise-grade cloud platform accelerates the time-to-market for IoT solutions, announced the Exosite IoT Alliance, a collaboration of edge devices, communication, business systems and software, and solution providers. The Exosite IoT Alliance is an ecosystem of like-minded companies and technology providers focused on advancing innovation in the digital enterprise and accelerating the overall adoption of IoT.
ATML: 8.78 (+0.32), MCHP: 44.41 (-0.23)
Dialog Semiconductor Announces Resolution in respect of the ATMEL Acquisition has been Passed at the General Meeting
Business Wire - Thu Nov 19, 7:45AM CST
Dialog Semiconductor plc (XETRA
LG) today announced that at an extraordinary general meeting of shareholders held today, the Dialog shareholders have approved the allocation of shares required to complete the company's previously announced acquisition of Atmel Corporation (NASDAQ: ATML). The resolution was approved by a vote of 61.94% of the shares represented at the meeting. ATML: 8.78 (+0.32)
Shareholder Resolution in Favor of the Acquisition of Atmel Has Been Passed at the General Meeting of Dialog Semiconductor
Business Wire - Thu Nov 19, 7:45AM CST
On 20 September 2015, Dialog Semiconductor Plc (XTRA: DLG) ("Dialog"
announced that it had entered into a merger agreement pursuant to which it will acquire Atmel Corporation (NASDAQ: ATML). The acquisition is subject to a resolution by Dialog's shareholders granting authority to the board of directors of Dialog to issue and allot new shares in Dialog (the "Resolution" . At today's General Meeting of Dialog, the Resolution has been passed. The total number of shares in issue as at 12.00 noon GMT (1.00 p.m. CET) on 17 November 2015 was 77,865,955 shares. The total number of votes cast was 42,312,471 or 54.34% of the issued share capital. The result of the poll was 26,209,631 or 61.94% votes "For", 16,102,840 or 38.06% votes "Against". ATML: 8.78 (+0.32)
